首页 > 最新文献

Clinical and Molecular Hepatology最新文献

英文 中文
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease. 评估代谢功能障碍相关脂肪性肝病晚期纤维化的基本工具。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-11 DOI: 10.3350/cmh.2024.0823
Won Sohn
{"title":"Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease.","authors":"Won Sohn","doi":"10.3350/cmh.2024.0823","DOIUrl":"https://doi.org/10.3350/cmh.2024.0823","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contemporary Awareness of Viral Hepatitis between 2012 and 2022 among Korean Adults. 2012 年至 2022 年韩国成年人对病毒性肝炎的当代认识。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-08 DOI: 10.3350/cmh.2024.0849
Donghee Kim, Won Kim, Aijaz Ahmed
{"title":"Contemporary Awareness of Viral Hepatitis between 2012 and 2022 among Korean Adults.","authors":"Donghee Kim, Won Kim, Aijaz Ahmed","doi":"10.3350/cmh.2024.0849","DOIUrl":"https://doi.org/10.3350/cmh.2024.0849","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details. 用于评估自身免疫性肝病肝纤维化的瞬态弹性成像:性能卓越,但细节有限。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-08 DOI: 10.3350/cmh.2024.0827
Kyung-Ah Kim
{"title":"Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details.","authors":"Kyung-Ah Kim","doi":"10.3350/cmh.2024.0827","DOIUrl":"https://doi.org/10.3350/cmh.2024.0827","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence on the Editorial regarding "The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients". 关于 "使用瞬态弹性成像预测慢性乙型肝炎患者的肝细胞癌 "社论的通信。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-07 DOI: 10.3350/cmh.2024.0846
Young-Joo Jin, Seung Up Kim
{"title":"Correspondence on the Editorial regarding \"The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients\".","authors":"Young-Joo Jin, Seung Up Kim","doi":"10.3350/cmh.2024.0846","DOIUrl":"https://doi.org/10.3350/cmh.2024.0846","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the impact on digestive disease in the post-COVID-19 condition. 了解后 COVID-19 条件对消化系统疾病的影响。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-07 DOI: 10.3350/cmh.2024.0856
Yang-Hyun Baek
{"title":"Understanding the impact on digestive disease in the post-COVID-19 condition.","authors":"Yang-Hyun Baek","doi":"10.3350/cmh.2024.0856","DOIUrl":"https://doi.org/10.3350/cmh.2024.0856","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. 经动脉放射栓塞术和酪氨酸激酶抑制剂对伴有门静脉血栓形成的肝癌的治疗效果比较。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-07 DOI: 10.3350/cmh.2024.0832
Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li
{"title":"Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.","authors":"Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li","doi":"10.3350/cmh.2024.0832","DOIUrl":"https://doi.org/10.3350/cmh.2024.0832","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence on Letter regarding "Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors". 关于 "使用免疫检查点抑制剂治疗肝细胞癌的个性化方法 "信函的通信。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-07 DOI: 10.3350/cmh.2024.0830
Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
{"title":"Correspondence on Letter regarding \"Personalized Approaches to the Treatment of Hepatocellular Carcinoma Using Immune Checkpoint Inhibitors\".","authors":"Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee","doi":"10.3350/cmh.2024.0830","DOIUrl":"https://doi.org/10.3350/cmh.2024.0830","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Urgent Need for Multidisciplinary Approaches in Managing Alcohol-Associated Liver Disease. 管理酒精相关肝病急需多学科方法。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-07 DOI: 10.3350/cmh.2024.0847
Soon Sun Kim, Jae Youn Cheong
{"title":"The Urgent Need for Multidisciplinary Approaches in Managing Alcohol-Associated Liver Disease.","authors":"Soon Sun Kim, Jae Youn Cheong","doi":"10.3350/cmh.2024.0847","DOIUrl":"https://doi.org/10.3350/cmh.2024.0847","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correspondence on Letter regarding "Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response." 关于 "预测联合免疫疗法反应的晚期肝细胞癌组织转录组特征 "信函的通信。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-07 DOI: 10.3350/cmh.2024.0829
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
{"title":"Correspondence on Letter regarding \"Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response.\"","authors":"Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee","doi":"10.3350/cmh.2024.0829","DOIUrl":"https://doi.org/10.3350/cmh.2024.0829","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-testing strategy to eliminate Hepatitis C as per WHO's goal: Analysis of disease burden and cost-effectiveness. 按照世界卫生组织的目标消除丙型肝炎的自我检测战略:疾病负担和成本效益分析。
IF 14 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-04 DOI: 10.3350/cmh.2024.0484
Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Background/aims: The World Health Organization (WHO) aims to eliminate hepatitis C Virus (HCV) by 2030, therefore, widespread HCV screening is required. The WHO recommends HCV self-testing (HCVST) as a new approach. We aimed to evaluate disease burden reduction using the HCVST screening strategy and identify the most cost-effective approach.

Methods: We developed a dynamic open-cohort Markov model to assess the long-term effects and cost-effectiveness of HCVST in the Republic of Korea from 2024 to 2030. Strategies for comparison included universal, birth cohort, high-risk group screening, and no screening, focusing on the following: (1) incremental cost-effectiveness ratio (ICER) per disability-adjusted life-year (DALY) saved; (2) severe liver disease cases; and (3) liver-related death reduction.

Results: Universal HCVST screening is the most effective strategy for achieving the WHO goal by 2030, substantially lowering the incidence of severe liver disease by 71% and preventing liver-related deaths by 69 %, thereby averting 267,942 DALYs. Moreover, with an ICER of $8,078 per DALY and high cost-effectiveness, the sensitivity results prove that cost-effectiveness is robust. Although high-risk group screening offers the lowest cost compared with other strategies, its effectiveness in preventing severe liver disease is minimal, falling short of the current WHO goal.

Conclusions: Our study confirms that universal HCVST screening is a cost-effective strategy aligned with the WHO goal to eliminate HCV by 2030. Despite its higher costs compared to risk-based screening, the disease burden can be significantly reduced by providing effective HCVST access to individuals who might otherwise not be tested.

背景/目的:世界卫生组织(WHO)的目标是到 2030 年消除丙型肝炎病毒(HCV),因此需要广泛开展 HCV 筛查。世卫组织建议将丙型肝炎病毒自我检测(HCVST)作为一种新方法。我们的目的是评估采用 HCVST 筛查策略可减少的疾病负担,并确定最具成本效益的方法:我们建立了一个动态开放队列马尔可夫模型,以评估 2024 年至 2030 年期间大韩民国 HCVST 的长期效果和成本效益。比较策略包括普遍筛查、出生队列筛查、高危人群筛查和不筛查,重点关注以下几点:(1) 每挽救一个残疾调整生命年(DALY)的增量成本效益比(ICER);(2) 严重肝病病例;以及 (3) 减少与肝脏相关的死亡:结果:普及 HCVST 筛查是到 2030 年实现世卫组织目标的最有效策略,可将重症肝病发病率大幅降低 71%,将与肝脏相关的死亡预防率降低 69%,从而避免 267,942 个残疾调整生命年。此外,每 DALY 的 ICER 为 8,078 美元,具有很高的成本效益,敏感性结果证明成本效益是稳健的。尽管与其他策略相比,高危人群筛查的成本最低,但其在预防严重肝病方面的效果却微乎其微,没有达到世界卫生组织目前的目标:我们的研究证实,普及 HCVST 筛查是一项具有成本效益的策略,符合世卫组织到 2030 年消除 HCV 的目标。尽管与基于风险的筛查相比成本较高,但通过为原本可能无法接受检测的人提供有效的 HCVST 检测,可以显著减轻疾病负担。
{"title":"Self-testing strategy to eliminate Hepatitis C as per WHO's goal: Analysis of disease burden and cost-effectiveness.","authors":"Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn","doi":"10.3350/cmh.2024.0484","DOIUrl":"https://doi.org/10.3350/cmh.2024.0484","url":null,"abstract":"<p><strong>Background/aims: </strong>The World Health Organization (WHO) aims to eliminate hepatitis C Virus (HCV) by 2030, therefore, widespread HCV screening is required. The WHO recommends HCV self-testing (HCVST) as a new approach. We aimed to evaluate disease burden reduction using the HCVST screening strategy and identify the most cost-effective approach.</p><p><strong>Methods: </strong>We developed a dynamic open-cohort Markov model to assess the long-term effects and cost-effectiveness of HCVST in the Republic of Korea from 2024 to 2030. Strategies for comparison included universal, birth cohort, high-risk group screening, and no screening, focusing on the following: (1) incremental cost-effectiveness ratio (ICER) per disability-adjusted life-year (DALY) saved; (2) severe liver disease cases; and (3) liver-related death reduction.</p><p><strong>Results: </strong>Universal HCVST screening is the most effective strategy for achieving the WHO goal by 2030, substantially lowering the incidence of severe liver disease by 71% and preventing liver-related deaths by 69 %, thereby averting 267,942 DALYs. Moreover, with an ICER of $8,078 per DALY and high cost-effectiveness, the sensitivity results prove that cost-effectiveness is robust. Although high-risk group screening offers the lowest cost compared with other strategies, its effectiveness in preventing severe liver disease is minimal, falling short of the current WHO goal.</p><p><strong>Conclusions: </strong>Our study confirms that universal HCVST screening is a cost-effective strategy aligned with the WHO goal to eliminate HCV by 2030. Despite its higher costs compared to risk-based screening, the disease burden can be significantly reduced by providing effective HCVST access to individuals who might otherwise not be tested.</p>","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Molecular Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1